Systemic dissemination of viral vectors during intratumoral injection.
Intratumoral injection is a routine method for local viral gene delivery that may improve interstitial transport of viral vectors in tumor tissues and reduce systemic toxicity. However, the concentration of transgene products in normal organs, such as in the liver, may still exceed normal tissue tolerance if the products are highly toxic. The elevated concentration in normal tissues is likely to be caused by the dissemination of viral vectors from the tumor. Therefore, we investigated transgene expression in the liver, the serum, and a mouse mammary carcinoma (4T1) in mice after intratumoral injection of adenoviral vectors for mouse interleukin-12, luciferase, enhanced green fluorescence protein, or beta-galactosidase. We also performed numerical simulations of virus transport in tumors after intratumoral injection, based on the Krogh cylinder model. Our experimental data and numerical simulations demonstrated that virus dissemination was significant in mice and it occurred mainly during the intratumoral injection. To reduce virus dissemination, we mixed these vectors with a viscous alginate solution and injected the mixture into the tumors. Our data showed that the alginate solution could significantly reduce virus dissemination while having minimal effects on transgene expression in tumors and on interleukin-12-induced tumor growth delay. These data suggest that virus dissemination is a potential problem in local viral gene therapy of cancer and that the dissemination could be significantly reduced by the alginate solution without compromising the efficacy of gene therapy.
Wang
Yong
Y
Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Hu
Jim Kang
JK
Krol
Ava
A
Li
Yong-Ping
YP
Li
Chuan-Yuan
CY
Yuan
Fan
F
D000256:Adenoviridae / Q000235:genetics / Q000502:physiology; D000818:Animals; D045744:Cell Line, Tumor; D004815:Epidermal Growth Factor / Q000032:analysis / Q000235:genetics; D015870:Gene Expression; D017930:Genes, Reporter / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000009:adverse effects / Q000032:analysis / Q000235:genetics*; D018664:Interleukin-12 / Q000032:analysis / Q000235:genetics; D008099:Liver / Q000378:metabolism; D008156:Luciferases / Q000032:analysis / Q000235:genetics; D051379:Mice; D009368:Neoplasm Transplantation; D019076:Transgenes / Q000235:genetics*
D018664:Interleukin-12; D004815:Epidermal Growth Factor; D008156:Luciferases